CSI Market
Sign In | Register

Castle Biosciences Inc (CSTL) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access CSTL quarterly Cash Flow →
Cash flow data covering Castle Biosciences Inc–Dec 31 2021 offers a view into how Dec 31 2025's cash position has developed alongside business activity.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-24.16
Depreciation & amortization40.77
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-2.14
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation45.89
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Embedded Derivative Gain Loss On Embedded Derivative Net-
Other Non Cash Interest-
Increase Decrease In Operating Lease Right Of Use Assets1.37
Increase Decrease In Operating Lease Liability-1.28
Equity Securities Fv Ni Gain Loss-1.47
Income taxes-6.23
Losses/ -gains on Investments net0.00
Accounts Receivable12.61
Increase (Decrease) in Accounts Payable3.08
Increase (Decrease) in Other Accrued Liabilities0.87
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.54
Other Working Capital-0.37
Other Noncash Income (Expense)0.15
Other net0.00
Payments for (Proceeds from) Other Operating Activities-4.22
Discontinued operations0.00
Net Cash flow from Operating Activities64.35
Investing Activities
Capital Expenditures-36.02
Sale of Capital Items0.05
Proceeds from Sale and Maturity of Marketable Securities189.20
Payments to Acquire Available-for-sale Securities, Debt-194.28
Real Estate Investments0.00
Payments To Acquire Asset Acquisitions Net Of Cash Acquired-18.73
Proceeds From Previous Asset Acquisition-
Asset Acquisition Adjustment To Purchase Price-
Proceeds From Sale Of Equity Securities Fv Ni1.53
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Payments to Acquire Finance Receivables-2.11
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-60.37
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock4.62
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-11.47
Proceeds From Issuance Of Term Debt And Preferred Stock Warrants Net Of Issuance Costs-
Proceeds From Issuance Of Convertible Debt And Common Stock Warrants Net Of Issuance Costs-
Finance Lease Principal Payments-0.12
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-6.96
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow28.37
Total Cash Flow-2.98
4 historic quarters locked

Sign in to unlock the full Castle Biosciences Inc cash flow history.

Sign In Create Free Account

About Castle Biosciences Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 26, 2026
  • Source: cstl-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001628280-26-012272

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License